OR WAIT null SECS
June 30, 2020
The expansion included adding new softgel encapsulation lines at its Strathroy, Canada and Sorocaba, Brazil sites for Catalent’s Vegicaps plant-based capsule and its CosmoPod twist-off capsule technologies.
June 29, 2020
The refurbishment provides enhanced glass melting power, improved glass distribution, and the production of transparent and amber type I glass bottles to meet the increase in demand for glass vials for vaccines and life-saving medicines.
The expansions included enhancing high-speed automatic syringe assembly and labeling, vial labeling and cartoning, and auto-injector assembly.
June 25, 2020
The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000L.
June 22, 2020
The facility has dedicated manufacturing and packaging for oral solid dosage forms, liquids, creams, and ointments.
The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.
June 18, 2020
The company will invest EUR 610 million (USD$682 million) into a new vaccine production site and research center in France.
June 17, 2020
Manufacturers are adapting with virtual work, remote monitoring, and re-evaluation of facility design to ensure worker safety.
June 16, 2020
The company is planning on adding up to 1.5 million sq. ft. of cGMP distribution space for COVID-19 shipments.
June 10, 2020
The investment will increase production lines for bulk drug substance and will add a fill/finish production line to the site.